Nabumetone pharmacokinetics in patients with varying degrees of renal impairment.
The pharmacokinetics of 1 g of oral nabumetone were studied in 20 patients divided into three groups according to the creatinine clearance rate of each. Pharmacokinetic assessment was made on the presence of the major and active metabolite found in the plasma, 6-methoxy-2-naphthylacetic acid, BRL 10720. Although the differences in the kinetic parameters measured in the three groups of patients were not statistically significant, that the drug should be used with care in patients with impaired renal function until additional data are available.
Boelaert
J R
JR
Department of Medicine, Algemeen Ziekenhuis St. Jan, Brugge, Belgium.
Jonnaert
H A
HA
Daneels
R F
RF
Schurgers
M L
ML
Thawley
A R
AR
Undre
N A
NA
Cooper
D L
DL
D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000493:pharmacokinetics*; D002074:Butanones / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D000077430:Nabumetone; D009280:Naphthaleneacetic Acids / Q000493:pharmacokinetics
D000894:Anti-Inflammatory Agents, Non-Steroidal; D002074:Butanones; D009280:Naphthaleneacetic Acids; C044612:6-methoxy-2-naphthylacetic acid; D000077430:Nabumetone